Single factor analysis showed that age, hypertension, coronary heart disease, left chest wall radiotherapy and anthracene sequential therapy were the risk factors for the cardiotoxicity related to anti-HER2-targeted therapy in early breast cancer (P < 0.05). This evidence concerns the gene ERBB2 and breast carcinoma.